These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 23529132

  • 1. Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects.
    Liang H, Tantiwong P, Sriwijitkamol A, Shanmugasundaram K, Mohan S, Espinoza S, Defronzo RA, Dubé JJ, Musi N.
    J Physiol; 2013 Jun 01; 591(11):2897-909. PubMed ID: 23529132
    [Abstract] [Full Text] [Related]

  • 2. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
    Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, DeFronzo RA.
    Diabetes; 2014 Aug 01; 63(8):2812-20. PubMed ID: 24353180
    [Abstract] [Full Text] [Related]

  • 3. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov 01; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 4. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
    Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2007 Jun 01; 292(6):E1775-81. PubMed ID: 17299078
    [Abstract] [Full Text] [Related]

  • 5. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 6. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep 01; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 7. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov 01; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 8. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects.
    Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N.
    Diabetes; 2008 Oct 01; 57(10):2595-602. PubMed ID: 18633101
    [Abstract] [Full Text] [Related]

  • 9. Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects.
    Serlie MJ, Meijer AJ, Groener JE, Duran M, Endert E, Fliers E, Aerts JM, Sauerwein HP.
    J Clin Endocrinol Metab; 2007 Apr 01; 92(4):1524-9. PubMed ID: 17264178
    [Abstract] [Full Text] [Related]

  • 10. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A.
    J Clin Endocrinol Metab; 2001 Nov 01; 86(11):5324-9. PubMed ID: 11701699
    [Abstract] [Full Text] [Related]

  • 11. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H, Stanley TL, Suresh C, De Sousa-Coelho AL, Frontera WR, Syu S, Braun LR, Looby SE, Feldpausch MN, Torriani M, Lee H, Patti ME, Grinspoon SK.
    J Clin Endocrinol Metab; 2016 Mar 01; 101(3):1123-33. PubMed ID: 26691888
    [Abstract] [Full Text] [Related]

  • 12. Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals.
    Hjelholt AJ, Charidemou E, Griffin JL, Pedersen SB, Gudiksen A, Pilegaard H, Jessen N, Møller N, Jørgensen JOL.
    Diabetologia; 2020 Dec 01; 63(12):2641-2653. PubMed ID: 32945898
    [Abstract] [Full Text] [Related]

  • 13. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
    Blachère JC, Pérusse F, Bukowiecki LJ.
    Metabolism; 2001 Aug 01; 50(8):945-51. PubMed ID: 11474483
    [Abstract] [Full Text] [Related]

  • 14. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.
    J Clin Endocrinol Metab; 2016 Mar 01; 101(3):1249-56. PubMed ID: 26765576
    [Abstract] [Full Text] [Related]

  • 15. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec 01; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 16. Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels.
    Lehto HR, Pärkkä J, Borra R, Tuunanen H, Lepomaki V, Parkkola R, Knuuti J, Nuutila P, Iozzo P.
    J Clin Endocrinol Metab; 2012 Sep 01; 97(9):3277-84. PubMed ID: 22761459
    [Abstract] [Full Text] [Related]

  • 17. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
    Nam SY, Lee, Kim KR, Lee HC, Nam MS, Cho JH, Huh KB.
    Metabolism; 1996 May 01; 45(5):594-7. PubMed ID: 8622602
    [Abstract] [Full Text] [Related]

  • 18. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
    Piatti PM, Monti LD, Davis SN, Conti M, Brown MD, Pozza G, Alberti KG.
    Diabetologia; 1996 Jan 01; 39(1):103-12. PubMed ID: 8720610
    [Abstract] [Full Text] [Related]

  • 19. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar 01; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 20. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    Worm D, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen H.
    Eur J Endocrinol; 2000 Sep 01; 143(3):389-95. PubMed ID: 11022182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.